Risk factors for Clostridioides difficile infection among patients diagnosed with inflammatory intestinal and rheumatological diseases in the biologic era
IBD significantly increases the risk of CDI among patients treated with biologic therapy; although such treatments do not seem to individually increase the risk, the number of biologics received may be a new predictor of CDI.
Authors
- Luís Alcalá
- José Miranda-Bautista (ORCID: https://orcid.org/0000-0001-9539-1689)
- Elena Reigadas (ORCID: https://orcid.org/0000-0003-0609-1305)
- Alejandra García‐García (ORCID: https://orcid.org/0000-0001-7794-135X)
- Luis A. Menchen (ORCID: https://orcid.org/0000-0001-9490-3726)
- Patricia Muñóz (ORCID: https://orcid.org/0000-0001-5706-5583)
- Helena Martínez-Lozano (ORCID: https://orcid.org/0000-0002-6274-1686)
- Juan Carlos Nieto
- Ignacio Marín-Jiménez
- Paula Saralegui-Gonzalez
- Pablo Ramón Fueyo-Peláez
- María Elena Lobato-Matilla
Institutions
- Universidad Complutense de Madrid (ES)
- Instituto de Salud Carlos III (ES)
- Hospital General Universitario Gregorio Marañón (ES)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-02-08
- DOI
- https://doi.org/10.1186/s12876-025-03650-3
- Citations
- 3
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 4.19